Bayer Strengthens Drug Discovery Platform with US$2 B Vividion Buyout

By Debadrita Paul

Pharma Deals Review: Vol 2021 Issue 9 (Table of Contents)

Published: 22 Sep-2021

DOI: 10.3833/pdr.v2021.i9.2637     ISSN: 1756-7874

Section: Mergers & Acquisitions



Bayer has completed the acquisition of Vividion, which uses its proprietary platform to address conventionally undruggable targets in the areas of immunology and oncology...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details